Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
133 USD | +0.12% | +1.97% | -4.35% |
Jun. 05 | Agilent Technologies Insider Sold Shares Worth $254,540, According to a Recent SEC Filing | MT |
Jun. 05 | Agilent Technologies Seeks M&A | CI |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The opinion of analysts covering the stock has improved over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- With an expected P/E ratio at 29.23 and 26.74 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.35% | 38.8B | A | ||
+9.48% | 222B | B | ||
+13.72% | 195B | B- | ||
+23.79% | 148B | B- | ||
+33.39% | 113B | A- | ||
+4.75% | 66.45B | A- | ||
+3.16% | 50.03B | B+ | ||
-1.27% | 34.85B | - | ||
+22.61% | 30.98B | B+ | ||
+19.58% | 24.7B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A Stock
- Ratings Agilent Technologies, Inc.